#bnt162b2 — Public Fediverse posts

Immunogenicity, reactogenicity and #safety to assess #booster #vaccinations with #BNT162b2 or double-dose #mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) – final report, https://etidiohnew.blogspot.com/2026/02/immunogenicity-reactogenicity-and.html

Effectiveness of #BNT162b2 and #mRNA-1273 #JN1-adapted #vaccines against #COVID19-associated #hospitalisation and #death ..., https://etidiohnew.blogspot.com/2025/07/effectiveness-of-bnt162b2-and-mrna-1273.html

Effectiveness of #BNT162b2 and #mRNA-1273 #JN1-adapted #vaccines against #COVID19-associated #hospitalisation and #death ..., https://etidiohnew.blogspot.com/2025/07/effectiveness-of-bnt162b2-and-mrna-1273.html

Effectiveness of #BNT162b2 and #mRNA-1273 #JN1-adapted #vaccines against #COVID19-associated #hospitalisation and #death ..., https://etidiohnew.blogspot.com/2025/07/effectiveness-of-bnt162b2-and-mrna-1273.html

Effectiveness of #BNT162b2 and #mRNA-1273 #JN1-adapted #vaccines against #COVID19-associated #hospitalisation and #death ..., https://etidiohnew.blogspot.com/2025/07/effectiveness-of-bnt162b2-and-mrna-1273.html

Early #effectiveness of #BNT162b2 #KP2 #vaccine against #COVID19 in #US VA #Healthcare System, https://etidiohnew.blogspot.com/2025/04/early-effectiveness-of-bnt162b2-kp2.html

Early #effectiveness of #BNT162b2 #KP2 #vaccine against #COVID19 in #US VA #Healthcare System, https://etidiohnew.blogspot.com/2025/04/early-effectiveness-of-bnt162b2-kp2.html

Early #effectiveness of #BNT162b2 #KP2 #vaccine against #COVID19 in #US VA #Healthcare System, https://etidiohnew.blogspot.com/2025/04/early-effectiveness-of-bnt162b2-kp2.html

Early #effectiveness of #BNT162b2 #KP2 #vaccine against #COVID19 in #US VA #Healthcare System, https://etidiohnew.blogspot.com/2025/04/early-effectiveness-of-bnt162b2-kp2.html

Early #effectiveness of #BNT162b2 #KP2 #vaccine against #COVID19 in #US VA #Healthcare System, https://etidiohnew.blogspot.com/2025/04/early-effectiveness-of-bnt162b2-kp2.html

#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines

Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…

https://etidioh.wordpress.com/2024/11/07/immunologic-and-biophysical-features-of-the-bnt162b2-jn1-and-kp2-adapted-covid19-vaccines/

#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines

Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…

https://etidioh.wordpress.com/2024/11/07/immunologic-and-biophysical-features-of-the-bnt162b2-jn1-and-kp2-adapted-covid19-vaccines/

#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines

Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…

https://etidioh.wordpress.com/2024/11/07/immunologic-and-biophysical-features-of-the-bnt162b2-jn1-and-kp2-adapted-covid19-vaccines/

#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines

Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…

https://etidioh.wordpress.com/2024/11/07/immunologic-and-biophysical-features-of-the-bnt162b2-jn1-and-kp2-adapted-covid19-vaccines/

#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines

Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…

https://etidioh.wordpress.com/2024/11/07/immunologic-and-biophysical-features-of-the-bnt162b2-jn1-and-kp2-adapted-covid19-vaccines/

Persistence of immune responses of a self-amplifying RNA #COVID19vaccine (ARCT-154) versus #BNT162b2 - The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2824%2900060-4/fulltext “a booster dose of the novel #mRNAVaccine, #ARCT154, a self-amplifying mRNA (#saRNA) vaccine based on the #SARSCoV2 D614G variant (B.1), induced superior immunogenicity than BNT162b2 (Comirnaty; Pfizer–BioNTech) in BNT162b2-primed adults 1 month after administration.”

Persistence of immune responses of a self-amplifying RNA #COVID19vaccine (ARCT-154) versus #BNT162b2 - The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2824%2900060-4/fulltext “a booster dose of the novel #mRNAVaccine, #ARCT154, a self-amplifying mRNA (#saRNA) vaccine based on the #SARSCoV2 D614G variant (B.1), induced superior immunogenicity than BNT162b2 (Comirnaty; Pfizer–BioNTech) in BNT162b2-primed adults 1 month after administration.”

[Correspondence] Immune responses following #BNT162b2 #XBB15 #vaccination in patients on #haemodialysis in #Germany https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00783-1/fulltext?rss=yes

#Humoral and #cellular immune responses following #BNT162b2 #XBB15 #vaccination, Lancet Infect Dis.: https://doi.org/10.1016/S1473-3099(23)00690-4

#Cerebellar and brainstem #stroke possibly associated with #booster dose of #BNT162b2 (Pfizer-BioNTech) #COVID-19 #vaccine https://pubmed.ncbi.nlm.nih.gov/37147105/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1854v2hhZnt0mgKVJH6nZTbknw5s3TIKHPNU4VUvcT-3jqFIGc&fc=None&ff=20230508102045&v=2.17.9.post6+86293ac

#Cerebellar and brainstem #stroke possibly associated with #booster dose of #BNT162b2 (Pfizer-BioNTech) #COVID-19 #vaccine https://pubmed.ncbi.nlm.nih.gov/37147105/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1854v2hhZnt0mgKVJH6nZTbknw5s3TIKHPNU4VUvcT-3jqFIGc&fc=None&ff=20230508102045&v=2.17.9.post6+86293ac

#Cerebellar and brainstem #stroke possibly associated with #booster dose of #BNT162b2 (Pfizer-BioNTech) #COVID-19 #vaccine https://pubmed.ncbi.nlm.nih.gov/37147105/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1854v2hhZnt0mgKVJH6nZTbknw5s3TIKHPNU4VUvcT-3jqFIGc&fc=None&ff=20230508102045&v=2.17.9.post6+86293ac

#Cerebellar and brainstem #stroke possibly associated with #booster dose of #BNT162b2 (Pfizer-BioNTech) #COVID-19 #vaccine https://pubmed.ncbi.nlm.nih.gov/37147105/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1854v2hhZnt0mgKVJH6nZTbknw5s3TIKHPNU4VUvcT-3jqFIGc&fc=None&ff=20230508102045&v=2.17.9.post6+86293ac

Immunogenicity and safety in healthy adults of full dose versus half doses of #COVID19 #vaccine (#ChAdOx1-S or #BNT162b2) or full-dose #CoronaVac administered as a #booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in #Indonesia https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00800-3/fulltext?rss=yes

#Effectiveness of #BNT162b2 and #CoronaVac #COVID19 #vaccination against asymptomatic and symptomatic #infection of #SARS-CoV-2 #omicron #BA2 in #HK: a prospective cohort study, https://doi.org/10.1016/S1473-3099(22)00732-0

#Comparison of five Anti- #SARS-CoV-2 #antibody #assays across three doses of #BNT162b2 reveals insufficient #standardization of SARS-CoV-2 #serology, https://doi.org/10.1016/j.jcv.2022.105345